当前位置: X-MOL 学术Pediatr. Blood Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group
Pediatric Blood & Cancer ( IF 2.4 ) Pub Date : 2021-09-08 , DOI: 10.1002/pbc.29333
Anderson B Collier 1 , Mark D Krailo 2 , Ha M Dang 2 , Steven G DuBois 3 , Douglas S Hawkins 4 , Mark L Bernstein 5 , Lisa R Bomgaars 6 , Damon R Reed 7 , Richard G Gorlick 8 , Katherine A Janeway 3
Affiliation  

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

中文翻译:

参加合作组 2 期临床试验的复发或进展性尤文肉瘤患者的结果:来自儿童肿瘤组的报告

SevenChildren's Oncology Group 对复发/进展性实体瘤患者进行的 2 期试验进行了分析,以估计复发/进展性尤文肉瘤的无事件生存期 (EFS)。登记了 128 名尤文肉瘤患者,发生了 124 起事件。6 个月的 EFS 为 12.7%,表明这些患者的预后不佳。只有多西紫杉醇达到了方案规定的活性放射学反应率;然而,多西紫杉醇的 EFS 与其他药物相似,表明更高的放射学反应率可能不会转化为更好的疾病控制。该 EFS 基准可用作复发性尤文肉瘤试验的附加终点。
更新日期:2021-10-24
down
wechat
bug